share_log

This Biotech's Stock Could Double If Its Treatment for Major Depressive Disorder Succeeds, Says Mizuho

This Biotech's Stock Could Double If Its Treatment for Major Depressive Disorder Succeeds, Says Mizuho

瑞穗證券表示,如果該生物技術公司的治療嚴重抑鬱症的藥物成功,其股票可能翻倍。
MarketWatch ·  11/13 11:03

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論